Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?

Thilo Sprenger, Hilka Rothe, Klaus Jung, Hans Christiansen, Lena C Conradi, B Michael Ghadimi, Heinz Becker, Torsten Liersch, Thilo Sprenger, Hilka Rothe, Klaus Jung, Hans Christiansen, Lena C Conradi, B Michael Ghadimi, Heinz Becker, Torsten Liersch

Abstract

Background: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT.

Methods: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS).

Results: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001).

Conclusions: Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters.

Figures

Figure 1
Figure 1
Histopathologic differentiation: well/moderate differentiated residual tumor cell clusters after RCT with preserved glandular growth pattern (High Grade Tumors; Figure 1a). Poorly differentiated residual tumor cells with non-glandular formations (Low Grade Tumors; Figure 1b).
Figure 2
Figure 2
Distribution of ypT stage in 153 patients treated with preoperative RCT within clinical phase II/III trials. 107 patients (70%) manifested as intermediate responders with irradiation-induced tumor regression (TRG 2/3)[17] and ypT2 and ypT3 category.
Figure 3
Figure 3
DFS in patients with rectal cancer and intermediate response to preoperative RCT stratified by ypT stage (3a) and ypN stage (3b). OS in patients with rectal cancer and intermediate response to preoperative RCT stratified by ypT stage (3c) and ypN stage (3d).

References

    1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg. 1982;69:613–6. doi: 10.1002/bjs.1800691019.
    1. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–60. doi: 10.1016/0140-6736(93)90207-W.
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, Velde CJ van de. Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46. doi: 10.1056/NEJMoa010580.
    1. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–7. doi: 10.1056/NEJM199704033361402.
    1. Lavery IC, Fazio VW, Lopez-Kostner F. Radiotherapy for rectal cancer. N Engl J Med. 1997;337:346–7. doi: 10.1056/NEJM199707313370514. author reply 347-8.
    1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40. doi: 10.1056/NEJMoa040694.
    1. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rödel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C. [Update S3-guideline "colorectal cancer" 2008] Z Gastroenterol. 2008;46:799–840. doi: 10.1055/s-2008-1027726.
    1. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002;45:895–903. doi: 10.1007/s10350-004-6325-7.
    1. Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, Lapeyre M, Boissel P, Guillemin F, Bey P. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys. 1998;42:935–41.
    1. Rodel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96. doi: 10.1200/JCO.2005.02.1329.
    1. Miyoshi M, Ueno H, Hashiguchi Y, Mochizuki H, Talbot IC. Extent of mesorectal tumor invasion as a prognostic factor after curative surgery for T3 rectal cancer patients. Ann Surg. 2006;243:492–8. doi: 10.1097/01.sla.0000205627.05769.08.
    1. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum. 1999;42:167–73. doi: 10.1007/BF02237122.
    1. Steel MC, Woods R, Mackay JM, Chen F. Extent of mesorectal invasion is a prognostic indicator in T3 rectal carcinoma. ANZ J Surg. 2002;72:483–7. doi: 10.1046/j.1445-2197.2002.02457.x.
    1. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21:19–22. doi: 10.1002/ssu.10017.
    1. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G. European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379–86. doi: 10.1200/JCO.2007.11.9685.
    1. Gerard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5. doi: 10.1200/JCO.2006.06.7629.
    1. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19–23. doi: 10.1007/s003840050072.
    1. Nagtegaal ID, Velde CJ van de, Worp E van der, Kapiteijn E, Quirke P, van Krieken JH. Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729–34. doi: 10.1200/JCO.2002.07.010.
    1. Greene FL, Brierley J, O'Sullivan B, Sobin LH, Wittekind C. International Union Against Cancer and American Joint Committee on Cancer. On the use and abuse of X in the TNM classification. Cancer. 2005;103:647–9. doi: 10.1002/cncr.20808.
    1. UICC. TNM Supplement 2001. In: Wittekind Ch, Henson DE, Hutter RVP, Sobin LH, editor. A commentary on uniform use. 2. John Wiley & Sons, New York; 2001.
    1. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110–7. doi: 10.1200/JCO.2006.08.3675.
    1. Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, Brule AJ van den, Nieuwenhuijzen GA, van Krieken JH, Nagtegaal ID. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res. 2007;13:6617–23. doi: 10.1158/1078-0432.CCR-07-1197.
    1. Merkel S, Mansmann U, Papadopoulos T, Wittekind C, Hohenberger W, Hermanek P. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer. 2001;92:2754–9. doi: 10.1002/1097-0142(20011201)92:11<2754::AID-CNCR10083>;2-4.
    1. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709–15.
    1. Chang GJ, Rodriguez-Bigas MA, Eng C, Skibber JM. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer. 2009;115:5432–40. doi: 10.1002/cncr.24622.
    1. Kim TH, Chang HJ, Kim DY, Jung KH, Hong YS, Kim SY, Park JW, Oh JH, Lim SB, Choi HS, Jeong SY. Pathologic Nodal Classification Is the Most Discriminating Prognostic Factor for Disease-Free Survival in Rectal Cancer Patients Treated with Preoperative Chemoradiotherapy and Curative Resection. Int J Radiat Oncol Biol Phys. 2009. in press .
    1. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57–64. doi: 10.1002/cncr.23516.
    1. Baxter NN, Morris AM, Rothenberger DA, Tepper JE. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys. 2005;61:426–31.
    1. Habr-Gama A, Perez RO, Proscurshim I, Rawet V, Pereira DD, Sousa AH, Kiss D, Cecconello I. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean? Dis Colon Rectum. 2008;51:277–83. doi: 10.1007/s10350-007-9148-5.
    1. Wichmann MW, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, Angele MK, Schildberg FW. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg. 2002;137:206–10. doi: 10.1001/archsurg.137.2.206.
    1. Wijesuriya RE, Deen KI, Hewavisenthi J, Balawardana J, Perera M. Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly. Surg Today. 2005;35:442–5. doi: 10.1007/s00595-004-2956-5.
    1. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB, Cummings B, Gunderson L, Macdonald JS, Mayer RJ. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001;19:157–63.
    1. Morris EJ, Maughan NJ, Forman D, Quirke P. Identifying stage III colorectal cancer patients: the influence of the patient, surgeon, and pathologist. J Clin Oncol. 2007;25:2573–9. doi: 10.1200/JCO.2007.11.0445.
    1. Earle CC, Weiser MR, Ter Veer A, Skibber JM, Wilson J, Rajput A, Wong YN, Benson AB, Shibata S, Romanus D, Niland J, Schrag D. Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. J Surg Oncol. 2009;100:525–8. doi: 10.1002/jso.21373.
    1. Kim YW, Kim NK, Min BS, Lee KY, Sohn SK, Cho CH. The influence of the number of retrieved lymph nodes on staging and survival in patients with stage II and III rectal cancer undergoing tumor-specific mesorectal excision. Ann Surg. 2009;249:965–72. doi: 10.1097/SLA.0b013e3181a6cc25.
    1. Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum. 2006;49:1284–92. doi: 10.1007/s10350-006-0570-x.
    1. Huh JW, Kim HR. Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: Is it essential for patients with ypT0-2N0? J Surg Oncol. 2009;100:387–391. doi: 10.1002/jso.21342.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe